The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Developing aptamers into therapeutics
Open accessAbstract
Nucleic acid therapeuticsThe idea of using nucleic acid molecules as therapeutic agents was conceived in the 1970s with the development of antisense strategies.Antisense compounds are single-stranded nucleic acids that, in principle, disrupt the synthesis of a targeted protein by hybridizing in a sequence-dependent manner to the mRNAs that encode it.The mechanism of inhibition by nucleic acid aptamers is fundamentally different.Aptamers are single-stranded nucleic acids that directly inhibit a protein's function by folding into a specific three-dimensional structure that dictates high-affinity binding to the targeted protein.Through iterative in vitro selection techniques, aptamers can be generated that bind essentially any protein (or small molecule) target.A high-affinity, specific inhibitor can theoretically be made to order, provided that a small quantity of pure target is available.Because they inhibit the activity of existing proteins directly, aptamers are more similar to monoclonal antibody or small molecule drugs than to antisense compounds, and this property greatly increases the number of clinical indications that are potentially treatable by nucleic acid-based compounds.Aptamers have been generated against a wide variety of targets, a complete discussion of which is beyond the scope of this article (for review, see ref. 1).As with any molecular therapeutic approach, the inhibitor is only as effective as the target is important.Through their ability to specifically inhibit a molecule of interest, aptamers have already proven useful as reagents for target validation in a variety of disease models.The next step, therapeutic utility, will depend on the efficacy of these novel compounds in humans.In this Perspective, we will focus on the development and status of aptamers as therapeutic molecules. Nucleic acids as direct antagonists of protein functionMany viruses, including HIV, have evolved small, structured RNA sequences to recruit viral and host cell proteins to perform essential functions in viral replication.The HIV virus, for example, employs the TAR and RRE RNA sequences to recruit the essential viral regulatory proteins tat and rev, which aid in Developing aptamers into therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Selection of single-stranded DNA molecules that bind and inhibit human thrombin
Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H., & Toole, J. J. (1992) · Nature · doi:10.1038/355564a0 · Cited by 2,469
Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF
Ferns, G. A. A., Raines, E. W., Sprugel, K. H., Motani, A. S., Reidy, M. A., & Ross, R. (1991) · Science · doi:10.1126/science.1653454 · Cited by 1,065
DIVERSITY OF OLIGONUCLEOTIDE FUNCTIONS
Gold, L., Polisky, B., Uhlenbeck, O., & Yarus, M. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003555 · Cited by 805
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Morishita, R., Gibbons, G. H., Horiuchi, M., Ellison, K. E., Nakama, M., Zhang, L., Kaneda, Y., Ogihara, T., & Dzau, V. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.5855 · Cited by 479
Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes
Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., & Eckstein, F. (1991) · Science · doi:10.1126/science.1857967 · Cited by 463
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
Sullenger, B. A., Gallardo, H. F., Ungers, G. E., & Gilboa, E. (1990) · Cell · doi:10.1016/0092-8674(90)90455-n · Cited by 443
Self-citationMann, M. J., Whittemore, A. D., Donaldson, M. C., Belkin, M., Conte, M. S., Polak, J. F., Orav, E. J., Ehsan, A., Dell'Acqua, G., & Dzau, V. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)09405-2 · Cited by 402
Inhibitory DNA Ligands to Platelet-Derived Growth Factor B-Chain
Green, L. S., Jellinek, D., Jenison, R., Östman, A., Heldin, C.-H., & Janjic, N. (1996) · Biochemistry · doi:10.1021/bi961544+ · Cited by 390
VEGF165 mediates glomerular endothelial repair
Ostendorf, T., Kunter, U., Eitner, F., Loos, A., Regele, H., Kerjaschki, D., Henninger, D. D., Janjic, N., & Floege, J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6740 · Cited by 287
Griffin, L., Tidmarsh, G., Bock, L., Toole, J., & Leung, L. (1993) · Blood · doi:10.1182/blood.v81.12.3271.3271 · Cited by 285
Kohn, D. B., Bauer, G., Rice, C. R., Rothschild, J. C., Carbonaro, D. A., Valdez, P., Hao, Q.-L., Zhou, C., Bahner, I., Kearns, K., et al. (1999) · Blood · doi:10.1182/blood.v94.1.368.413a47_368_371 · Cited by 258
Novel Approach to Specific Growth Factor Inhibition in Vivo
Floege, J., Ostendorf, T., Janssen, U., Burg, M., Radeke, H. H., Vargeese, C., Gill, S. C., Green, L. S., & Janjic, N. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65263-7 · Cited by 233
Chemical Modification of Hammerhead Ribozymes
Beigelman, L., McSwiggen, J. A., Draper, K. G., Gonzalez, C., Jensen, K., Karpeisky, A. M., Modak, A. S., Matulic-Adamic, J., DiRenzo, A. B., Haeberli, P., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25702 · Cited by 229
Therapeutic applications of transcription factor decoy oligonucleotides
Mann, M. J., & Dzau, V. J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11459 · Cited by 217
Potent 2'-Amino-2'-deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor
Jellinek, D., Green, L. S., Bell, C., Lynott, C. K., Gill, N., Vargeese, C., Kirschenheuter, G., McGee, D. P. C., & Abesinghe, P. (1995) · Biochemistry · doi:10.1021/bi00036a009 · Cited by 215
Liposome-Anchored Vascular Endothelial Growth Factor Aptamers
Willis, M. C., Collins, B., Zhang, T., Green, L. S., Sebesta, D. P., Bell, C., Kellogg, E., Gill, S. C., Magallanez, A., Knauer, S., et al. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980002x · Cited by 181
Tucker, C. E., Chen, L.-S., Judkins, M. B., Farmer, J. A., Gill, S. C., & Drolet, D. W. (1999) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(99)00285-6 · Cited by 176
Liposome-Anchored Vascular Endothelial Growth Factor Aptamers
Willis, M. C., Collins, B. T., Zhang, T., Green, L. S., Sebesta, D. P., Bell, C. J., Kellogg, E. A., Gill, S. C., Magallanez, A., Knauer, S., et al. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980200o · Cited by 146
Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
Usman, N., & Blatt, L. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11631 · Cited by 137
2'-Fluoro and 2-amino-2'-deoxynucleoside 5'-triphosphates as substrates for T7 RNA polymerase
Aurup, H., Williams, D. M., & Eckstein, F. (1992) · Biochemistry · doi:10.1021/bi00155a016 · Cited by 137
Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides
Srinivasan, S. K., & Iversen, P. L. (1995) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1860090210 · Cited by 120
Lee, S., & Sullenger, B. A. (1997) · Nature Biotechnology · doi:10.1038/nbt0197-41 · Cited by 96
Self-citationPilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass
DeAnda, A., Coutre, S. E., Moon, M. R., Vial, C. M., Griffin, L. C., Law, V. S., Komeda, M., Leung, L. L. K., & Miller, D. C. (1994) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(94)92206-3 · Cited by 95
Blocking the Initiation of Coagulation by RNA Aptamers to Factor VIIa
Lyerly, H. K., Lawson, J., Rusconi, C., Yeh, A., & Sullenger, B. A. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614126 · Cited by 90
Self-citationLeppänen, O., Janjić, N., Carlsson, M.-A., Pietras, K., Levin, M., Vargeese, C., Green, L. S., Bergqvist, D., Östman, A., & Heldin, C. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.11.e89 · Cited by 82
Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function
Ishizaki, J., Nevins, J. R., & Sullenger, B. A. (1996) · Nature Medicine · doi:10.1038/nm1296-1386 · Cited by 73
Self-citationKhachigian, L. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11620 · Cited by 61
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Analytical applications of aptamers
Tombelli, S., Minunni, M., & Mascini, M. (2005) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2004.11.006 · Cited by 1,017
Electronic Aptamer‐Based Sensors
Willner, I., & Zayats, M. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200604524 · Cited by 818
Replacing antibodies with aptamers in lateral flow immunoassay
Chen, A., & Yang, S. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.04.041 · Cited by 551
Metadata
- Authors
- White, R. R., Sullenger, B. A., & Rusconi, C. P.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-10-15
- Volume
- 106
- Issue
- 8
- Pages
- 929-934
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2077130806
- Cited by
- 295
- References
- 31
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.